Liquidia Achieves Second Consecutive Profitable Quarter, Reports Strong YUTREPIA Sales and Positive 2025 Results
Summary
Liquidia Corporation reported strong fourth quarter and full year 2025 financial results, marking its second consecutive quarter of profitability with a net income of $14.6 million and positive non-GAAP adjusted EBITDA of $27.3 million in Q4 2025. The company achieved $148.3 million in product sales for YUTREPIA in 2025, driven by robust commercial launch metrics including over 3,600 unique patient prescriptions and an increase to approximately 860 prescribers. This financial strength positions Liquidia to fund its planned expansion of the sales force, new clinical studies for YUTREPIA, and advancement of L606 into pivotal trials from operations, reducing future dilution risk. Traders will view the sustained profitability and successful YUTREPIA launch as significant positive indicators for the company's growth trajectory.
At the time of this announcement, LQDA was trading at $32.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $11.26 to $46.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.